|Year : 2021 | Volume
| Issue : 4 | Page : 186-192
Impact of low early high-density lipoprotein cholesterol on inhospital outcome and short-term prognosis in patients with acute coronary syndrome
Tarek E Elkholy, Ekram S Saeed, Mahmoud A Abo Omar, Yasser H El-barbary
Department of Cardiology, Tanta University, Tanta, Egypt
|Date of Submission||18-Nov-2020|
|Date of Decision||01-Dec-2020|
|Date of Acceptance||14-Dec-2020|
|Date of Web Publication||25-Oct-2021|
Dr. Tarek E Elkholy
62 Elmotamyz District, 6th of October City, Giza
Source of Support: None, Conflict of Interest: None
Background: Acute coronary syndrome (ACS) is a cardiac emergency and constitutes a major burden globally. Association between serum lipid and ACS is established many years ago. Our study tried to have more information about the impact of high-density lipoprotein cholesterol (HDL-C) on inhospital outcome and short-term prognosis of patients with ACS. Materials and Methods: The study was a prospective comparative study. Clinical and chemical and interventional evaluation was done in hospital settings. A total number of 50 patients were included in the study and divided into two groups. Patients with low HDL-C level were in Group I and patients with normal HDL-C were in Group II. Results: Group I populations had more inhospital complications than Group II represented in acute heart failure (48% vs. 13%), cardiogenic shock (40% vs. 6%), complex coronary lesions (57% vs. 20%), and prolonged hospital stay (54% vs. 20%). A statistical significance was found regarding these variables (P < 0.05). Regarding the outcome after 1 month, it is observed that patients of Group I significantly experienced heart failure (59.38% vs. 21.43%) and worsening angina (62.5% vs. 28.57%) with a statistically significant difference. In contrast, there is no statistically significant difference regarding myocardial infarction, new cerebrovascular events, shock, and mortality. Conclusion: The study showed a strong association of HDL-C level with inhospital adverse events of ACS patients in addition to short-term adverse events. Complications of ACS were more in patients with low HDL-C level.
Keywords: Acute coronary syndrome, high-density lipoprotein cholesterol, ischemic heart disease
|How to cite this article:|
Elkholy TE, Saeed ES, Abo Omar MA, El-barbary YH. Impact of low early high-density lipoprotein cholesterol on inhospital outcome and short-term prognosis in patients with acute coronary syndrome. J Indian coll cardiol 2021;11:186-92
|How to cite this URL:|
Elkholy TE, Saeed ES, Abo Omar MA, El-barbary YH. Impact of low early high-density lipoprotein cholesterol on inhospital outcome and short-term prognosis in patients with acute coronary syndrome. J Indian coll cardiol [serial online] 2021 [cited 2021 Dec 5];11:186-92. Available from: https://www.joicc.org/text.asp?2021/11/4/186/329153
| Introduction|| |
Being able to have the prediction of the inhospital complications of patients with acute coronary syndrome (ACS) at the time of admission is of a great significance when trying to determine treatments. Consequently, many large studies tried to evaluate possible predictors of inhospital complications in ACS patients as well as short-term complications that may happen.
ACS includes many risk factors, such as aging, male gender, smoking, hypertension, diabetes mellitus, renal failure, obesity, hyperlipidemia, history of premature coronary artery disease (CAD), and sedentary lifestyle.
There is a solid clinical evidence showing that low high-density lipoprotein (HDL) is a pertinent risk factor for CAD due to reverse cholesterol transportation, anti-inflammatory, and antioxidant properties of HDL-C.,
A low level of HDL has been interrelated to be an important predictor for cardiovascular adverse effects. However, many people who survived of ACS have been involved in prospective studies to examine the use of statins for the secondary prevention of myocardial infarction; randomized-control trials have not recorded the initial lipid profile data of ACS at admission and during hospital stay of those patients.
Thus, the relation between the inhospital outcome and the HDL levels of samples drawn early after arrival remains undefined and poorly studied.
Furthermore, there is little information regarding the predictive value of the HDL cholesterol (HDL-C) levels for detecting cardiovascular events and their effect on early clinical outcomes after a hospital stay.
Aim of the work
Our aim is to evaluate the association between the low early HDL-C levels and inhospital adverse outcomes in addition to investigating the impact of HDL-C level on the early prognosis of ACS patients after receiving medical treatment or invasive treatment after 1 month from the hospital stay.
| Materials and Methods|| |
This prospective study was conducted in the Cardiology Department, Tanta University Hospital, within 6 months in the period from September 2019 to March 2020 and included 50 consecutive patients admitted to the emergency department or cardiac care unit with the diagnostic criteria for ACS with the aim to find the correlation between the level of HDL-C and inhospital outcome of those patients.
Classification of high-density lipoprotein
Patients were evaluated by HDL levels defined as low HDL levels (10–39 mg/dL), normal HDL level (40–59 mg/dL), and high HDL level (60–100 mg/dL). This grouping was chosen based on the classification of HDL levels by the Adult Treatment Panel III from the NCEP.
Then, patients were classified into two groups: Group I with HDL level in male ≥40 mg/dl and in female <50 mg/dl and Group II with HDL level in male ≥40 mg/dl and in female ≥50 mg/dl
Patients presented with ischemic symptoms (typical anginal chest pain, atypical chest discomfort, and/or acute onset breathlessness) lasting for 10 min at least within the last 24 h combined with either ST-segment changes (persistent ST-segment elevation in two successive leads or ST-segment depression of at least 0.5 mm or transient ST-segment elevation of 0.5–1.0 mm) and/or positive cardiac biomarkers (either elevated creatine kinase-MB (ck-mb or troponin levels).
Patients having a past history of percutaneous coronary intervention (PCI), coronary artery bypass graft, dilated cardiomyopathy, congenital heart diseases, and valvular affection; patients with serious comorbidities; and patients who refused to sign consent or with insufficient data were excluded from the study.
- All patients will be subjected to the following during hospital stay:
- Thorough history taking
- Complete clinical examination
- 12-lead electrocardiogram
- Transthoracic echocardiography
- Routine laboratory investigations including lipid profile within 24 h from patient's admission
- All patients will be treated either with PCI or medical treatment
- Inhospital adverse events of all the patients were evaluated (heart failure, arrhythmias, heart block, complexity of coronary artery lesions [left main lesion and/or three-vessel disease], cardiogenic shock, duration of hospitalization, cardiac arrest, and death).
All patients will be re-evaluated after 1 month of being discharged from the hospital and adverse outcomes will be evaluated as heart failure, myocardial infarction, worsening angina, new cerebrovascular events, cardiogenic shock, and death.
Analysis of data was done using the Statistical Package for the Social Sciences (SPSS) version 20 (Chicago, Illinois, USA). Qualitative data were described using number and percent. Quantitative data were described using range (minimum and maximum), mean, standard deviation, and median.
The tests include Chi-square test for categorical variables to compare between different groups, Fisher's Exact test for correction for Chi-square when >20% of the cells expected count <5, Student's t-test was used for normally distributed quantitative variables to compare between two studied groups, and Mann–Whitney test for abnormally distributed quantitative variables to compare between two studied groups.
Correlations between the different variables were done using Pearson correlation coefficient for the parametric data and Spearman correlation coefficient for the nonparametric data. P ≤ 0.05 was used as a cutoff value for the significance of results. Reliability analysis was performed by calculating the intraclass correlation coefficient between graders to assess inter-grader variation.
| Results|| |
Regarding symptoms, chest pain, either typical, atypical, or breathlessness, between the two groups was not significant with P values (0.797, 0.773, and 0.248), respectively. Similarly, a pattern of infarction between the two groups has no statistically significant difference as depicted in [Table 1].
There was no statistically significant difference between the two groups in respect to the age, sex, risk factors, and diagnosis as shown in [Table 2] and [Table 3].
|Table 3: Distribution of the study subjects according to the risk factors|
Click here to view
With respect to hemodynamic status, there was no much difference in mean pulse and blood pressure in the two groups with no statistical significance, whereas it is noted that ejection fraction was greatly lower in Group I than Group II with (P = 0.025) as mentioned in [Table 4]
Mean serum cholesterol and triglyceride levels were not significantly different between the two groups (P = 0.078 and P = 0.459, respectively). On the contrary, the mean low-density lipoprotein (LDL) was significantly low in Group I than in Group II (P = 0.026). In addition, the mean HDL-C was significantly less in Group I than Group II (P < 0.001) which was shown in [Table 5].
Regarding in-hospital adverse events, patients of group I developed acute decompensated heart failure (48.57% vs 13.33%, p= 0.019), severe coronary disease (57.14% vs 20% ,p=0.016) and cardiogenic shock (40% vs 16.67%, p= 0.018) more than group II with statistical significance. There is no statistical difference in arrhythmia (p= 0.0849), heart block, cardiac arrest (p= 0.607) and death (p=0.820) between two groups. In addition, group I patients had prolonged stay at hospital in contrast to group II patients (p<0.025) as provided in [Table 6].
|Table 6: Comparison of outcome during hospitalization between the two groups|
Click here to view
When we display the outcome after 1 month of discharge, it is noted that patients of Group I significantly experienced heart failure (59.38% vs 21.43%, P = 0.018) and worsening angina (62.5% vs. 28.57%, P = 0.034). In contrast, there is no statistically significant difference regarding myocardial infarction, new cerebrovascular events, shock, and mortality as described in [Table 7].
|Table 7: Comparison of individual postdischarge outcome between the two groups|
Click here to view
| Discussion|| |
It is generally postulated that patients with low HDL carry high liability to develop more adverse outcomes and mortality than those with normal to high HDL during hospital stay., However, evidences for this postulation are lacking. The only evidence of plasma lipids as prognostic factors is provided by Olsson et al., who evaluated the cohort of the MIRACL trial and demonstrated HDL-C as an independent predictor of events, as opposed to LDL-cholesterol. However, this result was obtained during a follow-up of 16 weeks and prediction of inhospital events was not evaluated, what makes our data original in regard to the focus of events during the acute phase of ACS.
The CRUSADE study and ACTION Registry-GWTG, two large studies, that studied the non-ST-segment elevated myocardial infarction assessed the HDL-C on the admission. However, both the registries revealed that patients with low HDL-C had a greater risk of inhospital death than those with normal HDL-C level; the primary data were lost in half of the patients in these studies. Moreover, similar studies analyzing the initial lipid measurements in ACS patients fail to show the interval between the arrival of patients and the time where the blood samples were taken.,
Our study was focused to get the relation of HDL-C with inhospital adverse events and short-term prognosis of patients with ACS.
Among 50 patients with ACS, we found that 35 (70%) patients had low HDL level. Roe MT et al. (2012) said that among NSTE-ACS patients, 18.1% had very low and 34.5% had low HDL-C level, which is slightly lower than our findings. Our study showed that the prevalence (70%) of low HDL-C in ACS patients was the greatest among other reported researches on ACS which were between 28% and 57%. One probable reason could be linked to the high incidence of metabolic syndrome in people of Egypt. In addition, a high percentage of metabolic syndrome and obesity has also been studied before in this region.
Our study revealed that the total number of males was more than the female patients (72% vs. 28%). Our finding had the support of Al-Rasadi et al. (77% vs. 23%), and Faizal et al. (80.63% vs. 19.37%).,
We found that chest discomfort was the most common complaint with its different patterns in both the groups of patients. The difference in presentation with typical chest pain and atypical chest pain between two groups was not significant (62.86% vs. 66.67%, P = 0.797) and (22.86% vs. 26.67%, P = 0.773), respectively. This was supported by Hermann et al. However, typical angina complaint is more prevalent in the two groups than the atypical angina.
Our study detected that difference in the history of smoking, high blood pressure, and DM was not significant statistically. The findings of our study were supported by the observations of Khan and Mojumder (2009), Al-Rasadi et al., Manurung, and Faizal et al.,,
Our study found that left ventricular function was affected in Group I patients. The mean ejection fraction of Group I was greatly lower than patients of Group II (P = 0.025); however, there was no great difference regarding pulse and blood pressure between the two groups.
Our findings revealed that more patients in Group I demonstrate a shock state than Group II during hospitalization (40% vs. 6.67%, P = 0.018). Similarly, Barter PJ et al. (2004). found that low HDL-C was linked to high incidence of cardiogenic shock, compared with the normal to high HDL-C group (P = 0.001).
The rate of cardiogenic shock in low HDL-C group is poorly studied, whereas in our study, low HDL-C was an independent determinant of cardiogenic instability in ACS. This could be explained in the correlation between low early HDL-C and severe coronary lesions, catecholamines and inotropes support, and/or use of assist devices. Furthermore, Zeller et al. showed that high blood sugar and low HDL-C levels had a solid relation with severe heart failure and hyperglycemia was an independent determinant of cardiogenic shock, and further studies are needed to confirm this new association between low HDL and cardiogenic shock.
Similarly, patients in Group I had higher rates of acute heart failure than those in Group II (48.57% vs. 13.33%, P = 0.019). This was supported by theories of Mehra, M.R., et al and Iwaoka, M., et al. of contribution of HDL dysfunction to the occurrence and development of heart failure. First, inflammation and heart failure are both connected. Second, heart failure is associated with insulin resistance. Both inflammation and insulin resistance cause HDL dysfunction. HDL dysfunction and heart failure could reinforce each other, a pattern of cyclic causality may be found,,
In contrast, these theories were contradicted by Faizal et al. (2009) and Al-Rasadi et al. who found no much difference between two groups of patients in regards to heart failure (23.5hi% vs 21%, p=0.029) and (CI=0.9-1.22, p=0.509) respectively.,
It is noted from our study that patients of Group I demonstrated severe coronary disease or multivessel disease more than those of Group II with statistical significance (57.14% vs. 20%, P = 0.016). This demonstrated that low HDL level is an important and independent risk factor for the severity of CAD which was supported by Salahuddin et al. and Wang et al. Several angiographic findings from ACS patients have detected an inverse relationship between the incidence of multivessel coronary lesions and the HDL level.,
Duration of hospital stay is affected by the level of HDL as demonstrated by our study as follows: patients with low HDL experienced prolonged hospital stay than those of normal or high HDL levels (54.29% vs. 20%, P = 0.025). This was supported by Al-Rasadi et al., Faizal et al., and Wolfram et al. (6.65 ± 2.04 vs. 5.09 ± 1.44 days, P < 0.001).,,
In addition, length of stay was longer among patients with low HDL-C (2.7–3.1 vs. 3.2–3.8 days, P = 0.02) according to Wolfram et al.
There is no statistically significant difference between the two groups in terms of arrhythmia, heart block, cardiac arrest, and death (P > 0.51). Our findings were supported by Chowdhury Muhammad Omar Faruque and Miftaul Jannath Chowdhury who revealed no difference in this regard (P > 0.05). Conversely, Al-Zakwani et al. and Correia et al. stated that low HDL level contributed to a high incidence of mortality.,
Our study was focused on assessing the correlation between the initial level of HDL at time of admission and the outcome of patients within 1 month after discharge.
Among 50 patients, 7 patients of Group I died, while only one patient of Group II passed away (20% vs. 6.667%, P = 0.239) which showed no much statistical significance in mortality between the two groups. This was supported by the findings of Zhixiong Zhong, Jingyuan Hou, and Qifeng Zhan which was as follows (52% vs. 82%, P = 0528). On the other side, the study of Wolfram et al. revealed that mortality up to 30 days was 0% in the high HDL group versus 3% (12 patients) in the low HDL group (P = 0.001).
Our study also demonstrated more patients who sustained left ventricular failure in Group I than their peers of Group II with statistical significance (59.38% vs. 21%, P = 0.018). Masayasu Izuhara supported that by showing that patients with low HDL develop heart failure more than those with satisfactory HDL (22% vs. 15%, P < 0.001).
Similarly, patients in Group I complained of frequent episodes of worsening angina more frequently than those of Group II (62.5% vs. 28.57%, P = 0.034).
In contrast, there is not much difference between the two groups regarding cardiogenic shock and cerebrovascular events.
Lipid blood levels may be somehow affected during the initial phase of ACS and this could have altered the estimation of HDL-C level. However, a study showed little variation in lipid levels which is measured in the first few days of admission after myocardial infarction. Furthermore, the sample size is small and number of patients is limited in comparison to other studies.
| Conclusion|| |
The study depicts a high incidence of low HDL levels in patients with ACS and was significantly associated with a higher rate of shock, complex coronary lesions, and acute heart failure but insignificantly associated with arrhythmia, heart block, cardiac arrest, and mortality during hospital stay. Low HDL also acts as a good prognostic factor for an increased incidence of heart failure and frequent angina episodes 30 days after ACS. Although guidelines for LDL management in ACS are well known, treatment guidelines concerning HDL levels are not as clear. Therefore, the failure to know the prognostic value of low HDL-C in ACS may predispose these patients to be liable for recurrent adverse events and worse results. Studies evaluating the clinical benefit of increasing HDL-C levels in patients with ACS must be more scrutinized and developed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gonzalez-Porras JR, Martin-Herrero F, Garcia-Sanz R, Lopez ML, Balanzategui A, Mateos MV, et al
. Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. Thromb Res 2007;119:691-8.
Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
Sacks FM, Expert Group on HDL cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2002;90:139-43.
Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, et al
. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial. Eur Heart J 2005;26:890-6.
Circulation NCEPEPoDJ. Treatment of high blood cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. 2002;106:3143-421.
Kirkpatrick L, Feeney B. A simple guide to IBM SPSS: For version 20.0. Nelson education Chicago, Illinois, USA 2012.
Correia LC, Rocha MS, Esteves JP. HDL-cholesterol level provides additional prognosis in acute coronary syndromes. Int J Cardiol 2009;136:307-14.
Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, et al
. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2008;29:2480-8.
Duffy D, Holmes DN, Roe MT, Peterson ED. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. Am Heart J 2012;163:705-13.
Acharjee S, Roe MT, Amsterdam EA, Holmes DN, Boden WE. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2013;112:1057-62.
Zaki ME, Hala T, El-Gammal M, Kamal S. Indicators of the metabolic syndrome in obese adolescents. Archives of Medical Science: AMS 2015;11, 92.
Alebshehy R, Shuaib NM, Mbako JD, Barffo D, Nuotol RK. Determinant analysis of obesity among adult females in Egypt. 2016;65:662-9.
Al-Rasadi K, Al-Zakwani I, Zubaid M, Ali A, Bahnacy Y, Sulaiman K, et al
. Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the Middle East. Open Cardiovasc Med J 2011;5:203-9.
Faizal P, Suresh S, Satheesh Kumar R, Augusti KT. A study on the hypoglycemic and hypolipidemic effects of an ayurvedic drug Rajanyamalakadi in diabetic patients. Indian J Clin Biochem 2009;24:82-7.
Hermann LK, Weingart SD, Yoon YM, Genes NG, Nelson BP, Shearer PL, et al
. Comparison of frequency of inducible myocardial ischemia in patients presenting to emergency department with typical versus atypical or nonanginal chest pain. Am J Cardiol 2010;105:1561-4.
Manurung D. Lipid profiles of acute coronary syndrome patients hospitalized in ICCU of Cipto Mangunkusumo Hospital. Acta Med Indones 2006;38:196-201.
Ishida M, Itoh T, Nakajima S, Ishikawa Y, Shimoda Y, Kimura T, et al
. A low early high-density lipoprotein cholesterol level is an independent predictor of in-hospital death in patients with acute coronary syndrome. Intern Med 2019;58:337-43.
Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, et al
. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005;165:1192-8.
Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant 2009;28:876-80.
Iwaoka M, Obata JE, Abe M, Nakamura T, Kitta Y, Kodama Y, et al
. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail 2007;13:247-53.
Salahuddin S, Siddiqui MA, Ahmad SI. Serum lipids and lipoproteins in patients with documented coronary artery disease. Pak J Pharm Sci 2004;17:85-92.
Wang XL, Tam C, McCredie RM, Wilcken DE. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994;89:1974-81.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al
. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, et al
. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 2013;128:1504-12.
Wolfram RM, Brewer HB, Xue Z, Satler LF, Pichard AD, Kent KM, et al
. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006;98:711-7.
Faruque CMO, Chowdhury AW, Chowdhury MJ, Hoque ATMM, Mia MS, Kabir SEJ, et al
. Association of HDL Cholesterol with In-Hospital Outcome of Patients with Acute Coronary Syndrome. Bangladesh Heart Journal 2017;32:114-8.
Al-Zakwani I, Sulaiman K, Al-Rasadi K, Mikhailidis DP. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Curr Med Res Opin 2011;27:879-85.
Zhong Z, Hou J, Zhang Q, Zhong W, Li B, Li C, et al
. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation. Lipids Health Dis 2019;18:40.
Izuhara M, Ono K, Shiomi H, Morimoto T, Furukawa Y, Nakagawa Y, et al
. High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: A report from the CREDO-Kyoto registry cohort-2. Atherosclerosis 2015;242:632-8.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al
. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, et al
. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol 2008;102:552-8.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]